Vera Therapeutics Reports Positive 2-Year Results for Kidney Drug TRUTAKNA

Key Facts

1The ORIGIN 3 final analysis showed TRUTAKNA stabilized eGFR and prevented kidney disease progression through two years.

In a move reflecting significant progress in the biotech sector's approach to chronic disease, Vera Therapeutics has released pivotal long-term clinical data. The final ORIGIN 3 analysis demonstrated that its drug TRUTAKNA (atacicept-vymj) effectively stabilized kidney function (eGFR) and prevented disease progression over a two-year period in patients with IgA Nephropathy. According to reports, the drug also achieved statistically significant reductions in proteinuria, marking a critical de-risking event for the company’s lead pipeline candidate.

This clinical validation comes as the pharmaceutical industry prioritizes treatments that can delay or prevent the need for dialysis and kidney transplantation. The data showed that TRUTAKNA's safety and efficacy profile remained favorable through 24 months, aligning with global treatment goals to reduce kidney function decline. These results serve as a milestone for the company as it prepares for upcoming regulatory submissions and potential full market approval.

Regarding market performance, VERA stock stood at $34.05 at close on September 14, 2026, after reaching a day high of $35.53 per market data. Investors should monitor the company's next steps, specifically the planned submission of a supplemental Biologics License Application (sBLA) to the FDA in the fourth quarter of 2026, which will be a primary catalyst for the stock's future valuation.